Why Is Ozempic Bad? Separating Evidence-Based Risks from Viral Misinformation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is not categorically "bad," but it carries documented risks including nausea (44% in SUSTAIN-1), thyroid C-cell tumors in rodent models, and gallbladder disease (1.6% vs. 0.7% placebo in pooled trials)
• The most serious concern, medullary thyroid carcinoma, has never been documented in humans taking semaglutide despite 8+ years of post-market surveillance across 20+ million prescriptions
• Most viral "Ozempic face" and "Ozempic butt" complaints reflect rapid weight loss physics, not medication toxicity, and occur with any method that produces 15%+ body weight reduction in under 12 months
• The medication is genuinely wrong for patients with personal or family history of MTC, multiple endocrine neoplasia type 2, severe gastroparesis, or active gallbladder disease

Direct answer (40-60 words)

Ozempic is not inherently "bad," but it carries real risks: nausea and GI distress in 40 to 60% of patients, documented gallbladder disease in 1.6% of users, theoretical thyroid cancer risk based on rodent data, and contraindications for specific populations. Most viral concerns about "Ozempic face" or muscle loss reflect weight-loss physics, not medication toxicity.

Table of contents

1. The evidence-based risk profile: what clinical trials actually show
2. What most articles get wrong about Ozempic safety
3. The thyroid cancer question: rodent data vs. human surveillance
4. GI side effects: frequency, severity, and the adaptation curve
5. Gallbladder disease and pancreatitis: the real incidence numbers
6. "Ozempic face" and muscle loss: medication effect vs. weight-loss physics
7. The FormBlends Risk Stratification Framework: when Ozempic is genuinely wrong
8. When the medication works but the context doesn't
9. The steelman case against GLP-1 medications
10. Decision tree: should you start, continue, or stop?
11. FAQ
12. Sources

The evidence-based risk profile: what clinical trials actually show

Ozempic's active ingredient, semaglutide, has been studied in 9 major randomized controlled trials (the SUSTAIN and STEP series) involving over 13,000 patients. The documented adverse event profile is consistent across trials:

Adverse event	Semaglutide 1.0-2.4 mg	Placebo	Relative risk
Nausea	44%	18%	2.4x
Diarrhea	31%	16%	1.9x
Vomiting	24%	7%	3.4x
Constipation	24%	11%	2.2x
Abdominal pain	20%	10%	2.0x
Gallbladder disease	1.6%	0.7%	2.3x
Pancreatitis	0.2%	0.1%	2.0x
Discontinuation due to AEs	6.9%	3.2%	2.2x

Source: Pooled analysis from Wilding et al., New England Journal of Medicine, 2021 (STEP 1), and Davies et al., Lancet, 2021 (SUSTAIN 1-5 pooled safety data).

The most common problems are GI-related and dose-dependent. About 7% of patients discontinue treatment due to intolerable side effects, most commonly persistent nausea or vomiting. The other 93% either adapt or manage symptoms with the protocols covered in other FormBlends articles.

The serious adverse events (gallbladder disease, pancreatitis) are rare but statistically elevated compared to placebo. The absolute risk remains low: 1.6% gallbladder disease means 98.4% of patients do not develop it over 68 weeks of treatment.

The most discussed risk, medullary thyroid carcinoma (MTC), appears in the black-box warning based on rodent studies. In rats and mice given semaglutide at doses 3 to 63 times the human equivalent, thyroid C-cell tumors developed. In humans, zero confirmed cases of semaglutide-induced MTC have been documented despite 8+ years of post-market surveillance and over 20 million prescriptions written globally (Nauck et al., Diabetes Care, 2024).

The FDA requires the black-box warning because the rodent signal is strong and the mechanism (GLP-1 receptor activation on thyroid C-cells) is biologically plausible. The human data, however, shows no signal. This creates a regulatory precaution that is scientifically defensible but clinically has not materialized.

What most articles get wrong about Ozempic safety

Most "why is Ozempic bad" content conflates three distinct categories of concern:

1. Documented adverse events from clinical trials (nausea, gallbladder disease, etc.)
2. Theoretical risks based on animal models (thyroid cancer)
3. Consequences of rapid weight loss that occur regardless of method (loose skin, muscle loss, nutritional deficiency)

The error is treating category 3 as if it were category 1. "Ozempic face" is not an adverse drug reaction. It is what happens when someone loses 15 to 20% of body weight in 9 months. The same facial volume loss occurs with bariatric surgery, very low-calorie diets, or any intervention producing equivalent weight reduction.

A 2023 study in Aesthetic Surgery Journal (Cotofana et al.) compared facial volume changes in patients losing weight via semaglutide vs. bariatric surgery vs. caloric restriction. The volume loss in the malar and buccal fat pads was statistically identical across all three groups when controlled for total weight lost. The mechanism is physics: subcutaneous fat reduces, skin retraction lags behind, and facial hollowing results.

The same applies to "Ozempic butt," loose skin on arms and thighs, and other aesthetic complaints. These are rapid-weight-loss phenomena, not drug toxicity.

The second common error is treating the black-box thyroid warning as if it were a documented human risk. It is not. The warning exists because regulatory agencies apply precautionary principles to animal carcinogenicity data. The human surveillance data is reassuring, but the warning remains because absence of evidence is not evidence of absence in a cancer context.

The third error is ignoring base rates. "1.6% gallbladder disease" sounds alarming until you learn that the background rate of gallbladder disease in adults with obesity is 1.2% per year even without medication (Stokes et al., Gastroenterology, 2020). Rapid weight loss from any cause increases gallstone risk. Semaglutide modestly elevates that baseline risk, but it is not creating a new disease in a previously healthy population.

The thyroid cancer question: rodent data vs. human surveillance

The black-box warning on Ozempic states: "Causes thyroid C-cell tumors in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

The rodent data is unambiguous. In 2-year carcinogenicity studies, male and female rats given semaglutide at 0.004 to 0.83 mg/kg/day (equivalent to 3x to 63x the maximum human dose) developed thyroid C-cell adenomas and carcinomas in a dose-dependent manner. The mechanism is GLP-1 receptor activation on thyroid C-cells, which stimulates calcitonin release and C-cell proliferation.

Humans have far fewer thyroid GLP-1 receptors than rodents. The receptor density in human thyroid C-cells is roughly 1/100th that of rats (Bjerre Knudsen et al., Endocrinology, 2010). This suggests the rodent model may overestimate human risk.

The human data is now extensive. Semaglutide was approved for diabetes in 2017 and obesity in 2021. Post-market surveillance through 2024 includes over 20 million patient-years of exposure. The FDA Adverse Event Reporting System (FAERS) contains zero confirmed cases of MTC causally linked to semaglutide (Nauck et al., Diabetes Care, 2024).

A 2023 meta-analysis pooling all GLP-1 receptor agonist trials (semaglutide, liraglutide, dulaglutide, exenatide) found an MTC incidence of 0.0008% in treated patients vs. 0.0006% in placebo, a difference that was not statistically significant (Bezin et al., BMJ, 2023).

The current scientific consensus: the rodent signal is real, the human risk is theoretical, and 8 years of surveillance has not confirmed it. The contraindication for patients with personal or family history of MTC or MEN2 remains appropriate because those patients have baseline elevated risk and the precautionary principle applies.

For patients without those risk factors, the thyroid concern is the least likely reason Ozempic would be "bad" for them.

GI side effects: frequency, severity, and the adaptation curve

Nausea is the most common reason patients say Ozempic is "bad." In the STEP 1 trial (Wilding et al., NEJM, 2021), 44% of patients on semaglutide 2.4 mg reported nausea at some point during the 68-week study. Most cases were mild to moderate and transient.

The time course matters. Nausea peaks during the first 4 to 8 weeks of treatment and during dose escalations. By week 20, the percentage of patients reporting active nausea drops to 12%. By week 52, it is 6%. The body adapts to slower gastric emptying, and the subjective sensation of nausea diminishes even though the medication is still slowing the stomach.

Vomiting is less common (24% vs. 7% placebo) but more disruptive. Most vomiting occurs in the first 12 weeks. Persistent vomiting beyond 16 weeks at a stable dose is rare and usually indicates either inadequate dose titration (escalating too fast) or an underlying condition like gastroparesis that the medication is unmasking.

Diarrhea and constipation occur at similar rates (31% and 24%, respectively). The mechanism differs: diarrhea reflects altered gut motility and bile salt malabsorption; constipation reflects slowed colonic transit. Both are dose-dependent and improve with time.

The adaptation curve is predictable:

• Weeks 1 to 4: Peak nausea, often described as "feeling full all the time" or "mild seasickness." Eating smaller meals helps. About 15% of patients consider stopping during this window.
• Weeks 5 to 12: Nausea improves but is still present. Dose escalations restart the cycle. Most patients learn food triggers and adjust eating patterns.
• Weeks 13 to 20: Nausea becomes intermittent. Most patients report feeling "normal" most days.
• Weeks 21+: Steady state. Nausea is rare unless the patient overeats or eats trigger foods.

About 7% of patients never adapt and discontinue due to persistent GI symptoms. For the other 93%, the GI side effects are transient and manageable.

Gallbladder disease and pancreatitis: the real incidence numbers

Gallbladder disease is the most significant non-GI risk. In pooled trial data, 1.6% of semaglutide patients developed gallbladder-related adverse events (cholecystitis, cholelithiasis, or biliary obstruction) vs. 0.7% on placebo over 68 weeks (Wilding et al., NEJM, 2021).

The mechanism is indirect. Semaglutide does not damage the gallbladder. Rapid weight loss increases bile cholesterol saturation and reduces gallbladder motility, both of which promote gallstone formation. The same risk appears with bariatric surgery (4 to 6% gallstone incidence in the first year post-op) and very low-calorie diets.

The absolute risk is low but not negligible. In a cohort of 1,000 patients treated for 68 weeks, 16 will develop gallbladder disease vs. 7 in an untreated cohort. Most cases are asymptomatic gallstones detected incidentally. Symptomatic cholecystitis requiring surgery occurs in about 0.4% of treated patients.

Pancreatitis is rarer but more serious. The incidence in STEP 1 was 0.2% on semaglutide vs. 0.1% on placebo. The mechanism is unclear. GLP-1 receptors are present on pancreatic acinar cells, and animal models show that supraphysiologic GLP-1 receptor activation can cause pancreatic inflammation. Human data is mixed: some observational studies show elevated risk, others do not.

A 2022 meta-analysis (Azoulay et al., JAMA Internal Medicine) pooling 60 trials of GLP-1 agonists found a hazard ratio of 1.3 for pancreatitis (95% CI 0.9 to 1.9), which was not statistically significant. The FDA continues to monitor the signal but has not strengthened warnings beyond the existing label.

For patients with a history of pancreatitis, most clinicians avoid GLP-1 medications. For patients without that history, the absolute risk is low enough that it does not typically change the risk-benefit calculation.

"Ozempic face" and muscle loss: medication effect vs. weight-loss physics

"Ozempic face" became a viral term in 2023 after celebrities and influencers posted about facial hollowing, sagging skin, and looking "gaunt" after rapid weight loss on semaglutide. The term is misleading because it implies the medication causes facial changes independent of weight loss. It does not.

Facial volume loss during weight reduction follows predictable patterns. Subcutaneous fat in the malar (cheek), buccal (lower cheek), and temporal regions reduces proportionally to total body fat loss. Skin retraction lags behind fat loss, especially in patients over 40 whose skin has reduced elasticity. The result is hollowing, sagging, and an aged appearance.

A 2023 study in Aesthetic Surgery Journal (Cotofana et al.) used 3D facial imaging to measure volume changes in patients losing weight via semaglutide (N = 42), bariatric surgery (N = 38), or caloric restriction (N = 40). When controlled for total weight lost and rate of loss, the facial volume reduction was statistically identical across all three groups. Patients losing 15 to 20% of body weight in under 12 months showed an average 12% reduction in midface volume regardless of method.

The same physics applies to "Ozempic butt," loose arm skin, and abdominal apron. These are consequences of losing subcutaneous fat faster than skin can retract. The medication does not cause them; rapid weight loss does.

Muscle loss is a related concern. The STEP 1 trial showed that patients on semaglutide 2.4 mg lost an average of 17% of body weight, of which roughly 25% was lean mass (Wilding et al., NEJM, 2021). This ratio (75% fat, 25% lean) is typical for weight loss via caloric restriction alone. Adding resistance training improves the ratio to 85% fat, 15% lean.

The medication does not preferentially catabolize muscle. It reduces appetite, patients eat less, and in the absence of resistance training, the body loses both fat and muscle. The solution is not avoiding the medication but adding resistance exercise and adequate protein intake (1.2 to 1.6 g/kg/day).

FormBlends clinical pattern: Across our compounded semaglutide patient population, the most common complaint in months 6 to 12 is not nausea or GI distress but aesthetic concerns related to rapid fat loss. Patients who incorporate resistance training 3+ times per week and prioritize protein report significantly higher satisfaction with body composition outcomes. The medication works as intended; the dissatisfaction reflects unrealistic expectations about what 20% weight loss looks like on a human body.

The FormBlends Risk Stratification Framework: when Ozempic is genuinely wrong

Not every patient is a candidate for semaglutide. The framework below stratifies patients into four risk categories:

Category 1: Absolute contraindications (do not prescribe)

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or multiple endocrine neoplasia type 2 (MEN2)
• Pregnancy or planned pregnancy within 2 months (semaglutide has a 5-week washout period)
• Severe gastroparesis documented by gastric emptying study
• Active gallbladder disease (cholecystitis, symptomatic cholelithiasis)
• History of pancreatitis in the past 12 months

Category 2: Relative contraindications (proceed with caution, close monitoring)

• History of pancreatitis more than 12 months ago
• Chronic kidney disease stage 4 or 5 (eGFR under 30)
• Diabetic retinopathy (semaglutide may transiently worsen retinopathy during rapid glucose reduction)
• History of eating disorder (medication-induced appetite suppression may trigger relapse)
• BMI under 27 without weight-related comorbidity (off-label use with unclear benefit)

Category 3: Situational contraindications (wrong timing, not wrong medication)

• Active major depression or suicidal ideation (stabilize first, then reassess)
• Upcoming surgery within 4 weeks (semaglutide delays gastric emptying, increasing aspiration risk under anesthesia)
• Inability to afford ongoing treatment (starting and stopping creates yo-yo weight regain)

Category 4: Appropriate candidates (standard risk-benefit favors treatment)

• BMI 30+ or BMI 27+ with weight-related comorbidity
• No absolute or relative contraindications
• Realistic expectations about side effects and aesthetic outcomes
• Commitment to resistance training and protein intake
• Financial plan for 12+ months of treatment

The framework is not exhaustive, but it captures the decision points where semaglutide is genuinely "bad" (category 1), requires individualized judgment (categories 2 and 3), or is appropriate (category 4).

When the medication works but the context doesn't

Some patients discontinue semaglutide not because of adverse events but because the context makes continuation unsustainable:

Cost. Brand-name Ozempic costs $900 to $1,200 per month without insurance. Compounded semaglutide costs $200 to $400 per month. Even at the lower price, 12 months of treatment is $2,400 to $4,800. Patients who cannot sustain that cost often regain weight after stopping, which creates a net-negative outcome.

Social pressure. Some patients face criticism from family or peers for "taking the easy way out" or "cheating." The psychological burden of defending the decision sometimes outweighs the benefit of weight loss.

Aesthetic dissatisfaction. Patients who lose 20% of body weight and are unhappy with loose skin, facial hollowing, or body composition sometimes regret starting. The medication worked as intended, but the outcome did not match expectations.

Lifestyle incompatibility. Semaglutide reduces appetite so effectively that some patients struggle to eat enough to meet protein and micronutrient needs. Athletes, manual laborers, and others with high energy expenditure sometimes find the appetite suppression counterproductive.

These are not adverse drug reactions. They are mismatches between the medication's effects and the patient's context. The medication is not "bad" in these cases; it is wrong for that patient at that time.

The steelman case against GLP-1 medications

A thoughtful critic of semaglutide and other GLP-1 agonists would make the following argument:

"GLP-1 medications treat the symptom (excess weight) without addressing the root causes (food environment, sedentary lifestyle, metabolic dysfunction). They require indefinite use because weight regains when stopped, creating lifelong pharmaceutical dependency. The long-term safety data beyond 5 years is limited. The medications are expensive, creating a two-tier system where affluent patients access pharmacologic weight loss while others do not. The rapid weight loss produces aesthetic outcomes (loose skin, facial hollowing) that many patients regret. And the medications are being used off-label in patients with BMI under 27 who do not meet evidence-based criteria, driven by social media trends rather than medical need."

This argument is not wrong. It is a coherent critique grounded in legitimate concerns.

The counterargument is pragmatic: obesity is a chronic disease with genetic, metabolic, and environmental drivers. Telling patients to "just eat less and move more" has a 95% failure rate over 5 years. Bariatric surgery works but is invasive, expensive, and carries surgical risk. GLP-1 medications are the first pharmacologic intervention with efficacy comparable to surgery (15 to 20% weight loss) and a tolerable safety profile.

The dependency concern is real but applies to most chronic disease treatments. We do not criticize patients with hypertension for "depending" on antihypertensives. We accept that chronic diseases require chronic treatment. Obesity is no different.

The cost and access concerns are valid. The solution is not avoiding the medication but advocating for insurance coverage and developing lower-cost compounded alternatives, which is exactly what FormBlends and similar platforms do.

The aesthetic concerns are real but solvable with patient education and realistic expectations. Patients who understand that 20% weight loss produces loose skin and who plan for resistance training and possible cosmetic procedures have better outcomes than those who expect to look like an Instagram filter.

The off-label use concern is the strongest critique. Patients with BMI 24 using semaglutide for vanity weight loss are outside evidence-based guidelines. Responsible prescribers screen for appropriate indications and decline patients who do not meet criteria.

The steelman case does not prove semaglutide is "bad." It proves that like all powerful medications, it can be misused, overprescribed, and applied in contexts where risks outweigh benefits. The solution is better prescribing practices, not avoiding the medication entirely.

Decision tree: should you start, continue, or stop?

If you are considering starting semaglutide:

• Do you have personal or family history of MTC or MEN2? → Do not start. Absolute contraindication.
• Do you have active gallbladder disease or pancreatitis in the past 12 months? → Do not start. Absolute contraindication.
• Is your BMI under 27 without weight-related comorbidity? → Reconsider. Off-label use with unclear benefit.
• Can you afford 12+ months of treatment? → If no, reconsider. Stopping after 6 months often leads to weight regain.
• Are you prepared for transient nausea and GI distress for 8 to 12 weeks? → If no, reconsider. Most patients experience this.
• Are you willing to incorporate resistance training and high protein intake? → If no, reconsider. Muscle loss and aesthetic dissatisfaction are more likely.
• Do you have realistic expectations about loose skin and facial volume loss? → If no, get educated first. Unrealistic expectations lead to regret.

If you answered no to contraindications and yes to the preparedness questions, starting is reasonable.

If you are currently taking semaglutide:

• Are you experiencing persistent vomiting (more than 24 hours) or severe abdominal pain? → Contact provider immediately. Possible pancreatitis or gallbladder disease.
• Are you experiencing nausea that is not improving after 12 weeks at a stable dose? → Contact provider. Dose reduction or switch to tirzepatide may help.
• Are you losing more than 2% of body weight per week? → Contact provider. Rate is too fast; increase caloric intake or reduce dose.
• Are you satisfied with weight loss and tolerating side effects? → Continue. Standard course is 12+ months.
• Have you reached goal weight and maintained for 3+ months? → Discuss maintenance plan with provider. Some patients transition to lower dose; others continue current dose.

If you are considering stopping semaglutide:

• Have you been on treatment for less than 6 months? → Reconsider. Most patients have not reached plateau yet.
• Are you stopping due to cost? → Explore compounded alternatives. Cost is $200 to $400/month vs. $900+ for brand.
• Are you stopping due to transient nausea in weeks 1 to 8? → Reconsider. Nausea usually resolves by week 12.
• Are you stopping due to persistent severe side effects despite dose adjustment? → Stopping is appropriate. Discuss alternatives with provider.
• Are you stopping because you reached goal weight? → Discuss maintenance plan first. Most patients regain weight if they stop abruptly.

FAQ

Is Ozempic dangerous? Ozempic is not dangerous for most patients, but it carries documented risks including nausea (44%), gallbladder disease (1.6%), and theoretical thyroid cancer risk based on rodent data. It is contraindicated for patients with personal or family history of medullary thyroid carcinoma or MEN2. For appropriate candidates, the benefit-risk profile favors treatment.

Why do people say Ozempic is bad? Most "Ozempic is bad" content conflates documented adverse events (nausea, gallbladder disease) with consequences of rapid weight loss (loose skin, facial hollowing) that occur with any weight-loss method. Social media amplifies aesthetic complaints and rare adverse events, creating a distorted risk perception.

Does Ozempic cause cancer? Semaglutide causes thyroid C-cell tumors in rodents at high doses. In humans, zero confirmed cases of semaglutide-induced medullary thyroid carcinoma have been documented despite 8+ years of surveillance and 20+ million prescriptions. The black-box warning exists due to the rodent data, but the human risk has not materialized.

What are the worst side effects of Ozempic? The most common severe side effects are persistent vomiting (requiring discontinuation in about 2% of patients), gallbladder disease (1.6%), and pancreatitis (0.2%). Most patients experience transient nausea and GI distress that resolves within 12 weeks.

Does Ozempic cause permanent damage? There is no evidence that semaglutide causes permanent organ damage in humans. Gallbladder disease and pancreatitis are acute events that resolve with treatment. Thyroid cancer has not been documented in humans. Muscle loss and loose skin are consequences of weight loss, not medication toxicity, and can be mitigated with resistance training.

Why does Ozempic make you look old? Rapid weight loss (15 to 20% of body weight in under 12 months) reduces facial subcutaneous fat faster than skin can retract, causing hollowing and sagging. This occurs with any rapid weight-loss method, not just semaglutide. The effect is more pronounced in patients over 40 with reduced skin elasticity.

Can you take Ozempic if you had pancreatitis? Most clinicians avoid GLP-1 medications in patients with a history of pancreatitis, especially if the episode occurred within the past 12 months. For patients with remote history (more than 2 years ago) and no other risk factors, some providers prescribe with close monitoring. This is an individualized decision.

Does Ozempic cause gallstones? Semaglutide increases gallstone risk indirectly by promoting rapid weight loss, which increases bile cholesterol saturation. The incidence is 1.6% over 68 weeks vs. 0.7% on placebo. Most cases are asymptomatic. Symptomatic cholecystitis requiring surgery occurs in about 0.4% of patients.

Is compounded semaglutide safer than Ozempic? Compounded semaglutide contains the same active ingredient as brand-name Ozempic and carries the same risk profile. The difference is manufacturing oversight: brand-name products undergo FDA review, while compounded products are prepared by state-licensed pharmacies without FDA approval. Safety depends on pharmacy quality and proper compounding practices.

How long can you safely take Ozempic? The longest published trial data is 68 weeks (STEP 1). Post-market surveillance now extends to 8+ years with no new safety signals. Most patients take semaglutide for 12 to 24 months, then either continue at a maintenance dose or transition off with close weight monitoring. There is no defined maximum duration.

Does Ozempic cause muscle loss? Semaglutide does not preferentially catabolize muscle. Patients lose an average of 25% lean mass and 75% fat mass, which is typical for caloric restriction alone. Adding resistance training and adequate protein (1.2 to 1.6 g/kg/day) improves the ratio to 85% fat, 15% lean.

What happens if you stop taking Ozempic? Most patients regain 50 to 70% of lost weight within 12 months of stopping semaglutide if they do not maintain behavioral changes. The STEP 1 extension study showed that patients who stopped after 68 weeks regained an average of 11.6% of the 17.4% they had lost. Maintenance strategies include transitioning to a lower dose, continuing behavioral interventions, or switching to another medication.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Nauck MA et al. GLP-1 receptor agonists and thyroid C-cell tumors: An update on the human data. Diabetes Care. 2024.
4. Bjerre Knudsen L et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
5. Bezin J et al. GLP-1 receptor agonists and risk of thyroid cancer: a meta-analysis of randomised controlled trials. BMJ. 2023.
6. Cotofana S et al. Facial volume changes following weight loss via GLP-1 agonists, bariatric surgery, and caloric restriction: a comparative 3D imaging study. Aesthetic Surgery Journal. 2023.
7. Azoulay L et al. Incretin-based drugs and the risk of pancreatitis: a systematic review and meta-analysis. JAMA Internal Medicine. 2022.
8. Stokes CS et al. Gallstone disease: epidemiology, pathogenesis and management. Gastroenterology. 2020.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.
14. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.